Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer

July 20th 2023

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer

July 20th 2023

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

Pembrolizumab Plus Chemoradiotherapy Meets PFS End Point in High-Risk Locally Advanced Cervical Cancer

July 19th 2023

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, improved progression-free survival vs concurrent chemoradiotherapy alone in newly diagnosed patients with high-risk locally advanced cervical cancer.

Frontline SHR-1701 Plus BP102 and Chemo Shows Potent Activity in Cervical Cancer

July 18th 2023

The novel bifunctional fusion protein SHR-1701 combined with standard first-line treatment with the bevacizumab biosimilar BP102 and platinum-doublet chemotherapy produced high, durable responses and was deemed tolerable in patients with cervical cancer.

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

July 13th 2023

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Efficacy of Subsequent Therapies in Advanced Ovarian Cancer

July 13th 2023

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Immuno-Oncology Approaches Continue to Advance Across Gynecologic Cancers

July 11th 2023

Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.

Dr Gehrig on the Use of Genetic Testing in Endometrial Cancer

July 6th 2023

Paola Gehrig, MD, discusses the optimal use and timing of genetic testing in endometrial cancer.

Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer

July 6th 2023

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

Unmet Needs in the Maintenance Setting in Ovarian Cancer

July 6th 2023

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

Adverse Events Associated With Immunotherapy in the Treatment of Endometrial Cancer

July 4th 2023

Christian Marth, MD, PhD, reviews the adverse effects of pembrolizumab and lenvatinib in the treatment of endometrial cancer, as well as the patient experience with these treatments.

Treatment Strategies in Non-Responders to Chemotherapy

July 4th 2023

Bradley J. Monk, MD, FACS, FACOG, and Christian Marth, MD, PhD, share treatment approaches to patients with endometrial cancer with a low response rate to chemotherapy, highlighting a biomarker-based approach.

Dr Santin on the Clinical Activity of Sacituzumab Govitecan in Recurrent Endometrial Cancer

June 30th 2023

Alessandro Santin, MD, discusses the clinical activity of sacituzumab govitecan-hziy in patients with recurrent endometrial cancer who overexpress Trop-2.

Dr Huang on the Use of Neoadjuvant PARP Inhibitors in Advanced Ovarian Cancer

June 29th 2023

Marilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer: Outcomes by Blinded Independent Central Review of the RUBY trial (ENGOT-EN6-NSGO/GOG3031/RUBY)

June 29th 2023

Matthew Powell, MD, presents data from the blinded independent central review of the RUBY trial, which studied dostarlimab in patients with primary advanced or recurrent endometrial cancer.

Ovarian Cancer: Deciding Between Treatment Options

June 29th 2023

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

Frontline Maintenance Therapy in Ovarian Cancer

June 29th 2023

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

Future Outlook for Endometrial Cancer Treatment

June 27th 2023

Experts discuss the possibility to avoid use of chemotherapy by using immunotherapy.

Clinical Trials of Immunotherapies in Endometrial Cancer

June 27th 2023

Christian Marth, MD, PhD, and Bradley J. Monk, MD, FACS, FACOG, discuss data from the NRG GY018 and RUBY trials regarding the use of immunotherapies for the treatment of endometrial cancer.

Chemotherapy Options for Endometrial Cancer

June 20th 2023

Bradley J. Monk, MD, FACS, FACOG, reviews the available chemotherapy options for treating advanced and recurrent endometrial cancer, as well as compares notes with Christian Marth, MD, PhD, on his clinical experience.